Source: CureToday articles
Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting.
Recent Content
- (no title)
- (no title)
- Oral safusidenib begins trial as maintenance for high-grade glioma
- Outcomes of relapse after teclistamab therapy in multiple myeloma
- Canada agency backs coverage of new ovarian cancer drug
- (no title)
- Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
- Therapy wins rare pediatric disease designation for hard-to-treat glioma
- November shines a spotlight on pancreatic cancer awareness
- Cero seeking more safety, dosing data on T-cell therapy for AML